Vericel (VCEL) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.27
- Estimate
- $0.06
- Surprise
- +382.1%
- Revenue (period 2026-09-30)
- $85.4M
- Score today
- 5.8/10
Revenue source: xbrl.
How the report landed
Vericel (VCEL) beat the $0.06 estimate with adjusted EPS of $0.27 — a large 382.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates VCEL Hold at 5.8/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +382.1% surprise compares with a +168.3% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: Matricel GmbH
- Concentration risk — Supplier: MediWound
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $52.93
- Stop
- $49.22
The stock trades at 110.2× trailing but 61.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 77 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
VCEL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.65B
- P/E (fwd)
- 61.2
- P/E (ttm)
- 110.2
- 52-week range
- $28.95–$55.60
- Off 52-week high
- 4.8%
- RSI (14)
- 77
- Volume vs avg
- 0.75×
- Score today
- 5.8/10